Noom, the digital wellness platform, is facing increased scrutiny as legal and regulatory bodies examine its expanding business centered around weight-loss drugs, including GLP-1 medications. The company has positioned these drugs as tools to amplify the effects of its existing behavioral change programs, driving users toward other aspects of its platform, according to a report from Reuters in May 2025.
The heightened attention comes as several biotechnology companies are developing and bringing to market novel obesity treatments. Viking Therapeutics, for example, is developing a weight loss drug that acts on both GLP-1 and GIP receptors, a dual-agonist approach, as reported by Labiotech.eu in February 2026. This development underscores a broader industry trend toward more potent pharmacological interventions for weight management.
Digital health companies, including Ro, have already begun launching programs that integrate GLP-1 prescriptions, such as Wegovy and Ozempic, into their service offerings, as detailed by CNBC in May 2024. This trend suggests a growing convergence between digital health platforms and pharmaceutical solutions for obesity.
Noom’s strategy of incorporating prescription weight-loss drugs into its platform appears to be a deliberate effort to avoid the fate of companies like WeightWatchers, which struggled to adapt to the rise of these medications. By framing the drugs as “superpowers” for weight loss, Noom aims to maintain relevance in a rapidly evolving market, according to the Reuters report.
Forbes reported in February 2026 that several companies are offering doctor-guided weight loss programs that include prescription medications, diet tips, and ongoing support. This indicates a competitive landscape where access to both digital coaching and pharmaceutical interventions is becoming increasingly important.
The legal and regulatory scrutiny surrounding Noom’s weight-loss drug business remains ongoing, with no immediate resolution publicly available.
